Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.
Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
StandardStandard
Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease. / Hughes, D.; Hughes, D.A.; Bodger, K. et al.
2008. Papur a gyflwynwyd yn Welsh Health Economics Group, Swansea University, Wales, UK.
2008. Papur a gyflwynwyd yn Welsh Health Economics Group, Swansea University, Wales, UK.
Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
HarvardHarvard
Hughes, D, Hughes, DA, Bodger, K & Kikuchi, T 2008, 'Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.', Papur a gyflwynwyd yn Welsh Health Economics Group, Swansea University, Wales, UK, 3/01/01.
APA
Hughes, D., Hughes, D. A., Bodger, K., & Kikuchi, T. (2008). Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.. Papur a gyflwynwyd yn Welsh Health Economics Group, Swansea University, Wales, UK.
CBE
Hughes D, Hughes DA, Bodger K, Kikuchi T. 2008. Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease. Papur a gyflwynwyd yn Welsh Health Economics Group, Swansea University, Wales, UK.
MLA
Hughes, D. et al. Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.. Welsh Health Economics Group, Swansea University, Wales, UK, 03 Ion 0001, Papur, 2008.
VancouverVancouver
Hughes D, Hughes DA, Bodger K, Kikuchi T. Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.. 2008. Papur a gyflwynwyd yn Welsh Health Economics Group, Swansea University, Wales, UK.
Author
RIS
TY - CONF
T1 - Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.
AU - Hughes, D.
AU - Hughes, D.A.
AU - Bodger, K.
AU - Kikuchi, T.
PY - 2008/4/1
Y1 - 2008/4/1
M3 - Paper
T2 - Welsh Health Economics Group, Swansea University, Wales, UK
Y2 - 3 January 0001
ER -